NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity
Earlier in March 2026, the European Medicines Agency’s CHMP issued a positive opinion to expand Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) label to treat obesity and control hunger in adults and children 4 years and older with acquired hypothalamic obesity due to hypothalamic injury or impairment, adding to the drug’s existing rare obesity indications.
This European regulatory milestone, coming shortly after U.S. approval for acquired hypothalamic obesity, reinforces Rhythm’s focus on...